175 related articles for article (PubMed ID: 8266771)
1. Use of octreotide in the treatment of digestive neuroendocrine tumours. Seven year experience in 20 cases including 9 cases of metastatic midgut carcinoid and 5 cases of metastatic gastrinoma.
Fiasse R; Pauwels S; Rahier J; Jamar F; Ketelslegers JM; Hassoun A; de Longueville M
Acta Gastroenterol Belg; 1993; 56(3-4):279-91. PubMed ID: 8266771
[TBL] [Abstract][Full Text] [Related]
2. A single-centre experience with octreotide in the treatment of different hypersecretory syndromes in patients with functional gastroenteropancreatic neuroendocrine tumors.
Berković MC; Altabas V; Herman D; Hrabar D; Goldoni V; Vizner B; Zjacić-Rotkvić V
Coll Antropol; 2007 Jun; 31(2):531-4. PubMed ID: 17847934
[TBL] [Abstract][Full Text] [Related]
3. Case report: optimal tumor cytoreduction and octreotide with durable disease control in a patient with MEN-1 and Zollinger-Ellison syndrome-over a decade of follow-up.
Daniels LM; Khalili M; Morano WF; Simoncini M; Mapow BC; Leaf A; Bowne WB
World J Surg Oncol; 2019 Dec; 17(1):213. PubMed ID: 31818296
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors.
Frank M; Klose KJ; Wied M; Ishaque N; Schade-Brittinger C; Arnold R
Am J Gastroenterol; 1999 May; 94(5):1381-7. PubMed ID: 10235222
[TBL] [Abstract][Full Text] [Related]
5. Surgery on neuroendocrine tumours.
Akerström G; Hellman P
Best Pract Res Clin Endocrinol Metab; 2007 Mar; 21(1):87-109. PubMed ID: 17382267
[TBL] [Abstract][Full Text] [Related]
6. Sandostatin and the Belfast experience.
Buchanan KD; Collins JS; Varghese A; Johnston CF; Shaw C
Digestion; 1990; 45 Suppl 1():11-4; discussion 15-6. PubMed ID: 2159429
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis of non-Zollinger-Ellison syndrome, non-carcinoid syndrome, enteropancreatic neuroendocrine tumours.
Metz DC
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S153-9. PubMed ID: 10604121
[TBL] [Abstract][Full Text] [Related]
8. Treatment of gastrointestinal endocrine tumours with interferon-alpha and octreotide.
Creutzfeldt W; Bartsch HH; Jacubaschke U; Stöckmann F
Acta Oncol; 1991; 30(4):529-35. PubMed ID: 1713038
[TBL] [Abstract][Full Text] [Related]
9. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours.
Angeletti S; Corleto VD; Schillaci O; Moretti A; Panzuto F; Annibale B; Delle Fave G
Ital J Gastroenterol Hepatol; 1999; 31(1):23-7. PubMed ID: 10091100
[TBL] [Abstract][Full Text] [Related]
10. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR.
Tomassetti P; Migliori M; Corinaldesi R; Gullo L
Aliment Pharmacol Ther; 2000 May; 14(5):557-60. PubMed ID: 10792118
[TBL] [Abstract][Full Text] [Related]
11. Effect of somatostatin analogue (octreotide) on blood flow to endocrine tumors metastatic to the liver: angiographic evaluation.
Cho KJ; Vinik AI
Radiology; 1990 Nov; 177(2):549-53. PubMed ID: 2171015
[TBL] [Abstract][Full Text] [Related]
12. [Somatostatin analogue in the treatment of neuroendocrine gut tumors].
Ben Yosef R; Glaser B; Catane R
Harefuah; 1990 Jul; 119(1-2):15-8. PubMed ID: 2172125
[TBL] [Abstract][Full Text] [Related]
13. [Use of octreotide in the treatment of digestive endocrine tumors. A French multicenter study].
Blanchin M; James-Deidier A; Chaumet-Riffaud PD; Chayvialle JA
Presse Med; 1992 Apr; 21(15):697-702. PubMed ID: 1376476
[TBL] [Abstract][Full Text] [Related]
14. Management of gastroenteropancreatic endocrine tumors: the place of somatostatin analogues.
Arnold R; Frank M; Kajdan U
Digestion; 1994; 55 Suppl 3():107-13. PubMed ID: 7698532
[TBL] [Abstract][Full Text] [Related]
15. [Diagnostic and therapeutic strategies in Zollinger-Ellison syndrome associated with multiple endocrine neoplasia type I (MEN-I): experience of the Zollinger-Ellison Syndrome Research Group: Bichat 1958-1999].
Mignon M
Bull Acad Natl Med; 2003; 187(7):1249-58; discussion 1259-60. PubMed ID: 15146602
[TBL] [Abstract][Full Text] [Related]
16. [Therapy of endocrine gastrointestinal-pancreatic tumors with somatostatin analog octreotide].
Arnold R; Neuhaus C; Trautmann ME
Dtsch Med Wochenschr; 1992 Jul; 117(27):1067-71. PubMed ID: 1352235
[No Abstract] [Full Text] [Related]
17. [Neuroendocrine tumors of the gastrointestinal tract].
Arnold C
Praxis (Bern 1994); 2007 Jan; 96(1-2):19-28. PubMed ID: 17256557
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.
Toumpanakis C; Garland J; Marelli L; Srirajaskanthan R; Soh J; Davies P; Buscombe J; Caplin ME
Aliment Pharmacol Ther; 2009 Oct; 30(7):733-40. PubMed ID: 19573169
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group.
di Bartolomeo M; Bajetta E; Buzzoni R; Mariani L; Carnaghi C; Somma L; Zilembo N; di Leo A
Cancer; 1996 Jan; 77(2):402-8. PubMed ID: 8625251
[TBL] [Abstract][Full Text] [Related]
20. Effects of sandostatin on neuroendocrine tumours of the gastrointestinal system.
Buchanan KD
Recent Results Cancer Res; 1993; 129():45-55. PubMed ID: 8394596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
